Maxime Dougados — Endo Lab

article 2003

Development of a French short form of the WOMAC function scale based on the patients' and experts' perspective

article 1995

Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA ·doi:10.1007/bf02106098

Gonadotropin releasing hormone (GnRH) agonists have shown to be effective in the treatment of several sex-hormone-dependent conditions. However, their use could be limited by the bone loss they induce. To evaluate the use of nasal salmon ca…

article 1988

Hepatocellular carcinoma after danazol therapy.

Danazol, an inhibitor of pituitary gonadotropin, has been proposed in the treatment of systemic lupus erythematosus (SLE). We report the case of a female patient with SLE in whom a hepatocellular carcinoma was discovered after 4 years of tr…

article 1986

[Hormonal modulation in disseminated lupus erythematosus: the preliminary results with danazol and cyproterone acetate].

In an open prospective study, we have tested clinical efficacy and tolerance of two antigonadotropic drugs, that is danazol (D) and cyproterone-acetate (CA). This study was performed in 11 female patients ranging in age from 19 to 47 years,…

article 1985

[Increase in transaminases during treatment with danazol in lupus patients].